The present study was undertaken to investigate the effect of fenugreek galactomannan on intestinal glucose uptake in surviving diabetic rats. It explored their potential action with respect to lowering maltase, lactase, and sucrase activities in the small intestine of galactomannan-treated diabetic group compared to the diabetic control group. The findings indicate that the increase of blood glucose levels was significantly suppressed in the galactomannan-treated group than those in the diabetic rats. Moreover, the galactomannan isolated from fenugreek exhibited a prominent selective inhibitory effect against intestinal lipase activity. It was found to significantly delay the absorption of LDL-cholesterol and triglycerides and the increase in HDL-cholesterol. In addition, fenugreek galactomannan efficiently protect the hepatic function observed by the considerable decrease of aspartate and alanine transaminases (AST and ALT) and lactate deshydrogenase (LDH) contents in the serum of diabetic rats. The beneficial effects of fenugreek galactomannan were also evidenced by their capacity to inhibit diabetes-induced kidney injury through lowering the urea and creatinine content in plasma. Overall, the conclusion of the present study indicate that fenugreek galactomannan displays a number of promising properties and attributes for future applications as therapeutic agents in biotechnological and bioprocess-based technologies, particularly those interested in the development of anti-diabetic and hypolipidemic drugs.